March 13, 2015 by Chain Drug Review and Chain Drug Review
Nasdaq OMX Group, Nasdaq-100, Walgreens Boots Alliance, WBA
Business, Leading Headlines, News, Retail News
NEW YORK — The Walgreens Boots Alliance Inc. is slated to become part of the Nasdaq-100 Index later this month. The Nasdaq OMX Group Inc. said Friday that Walgreens Boots Alliance, which has the stock symbol WBA, will become a component of the Nasdaq-100 Index (NDX), Nasdaq-100 Equal Weighted Index (NDXE) and NASDAQ-100 Ex-Technology Index
March 13, 2015 by Chain Drug Review and Chain Drug Review
Rite Aid, Stefano Pessina, Walgreens Boots Alliance
CDR Blog
The “Walgreens looking to acquire Rite Aid” rumors have resurfaced following comments by Stefano Pessina, the billionaire investor and acting CEO of Walgreens Boots Alliance. A March 12 article by Reuters quoted Pessina, in remarks at the Retail Week Live conference in London, as saying that of potential deals to be made, “the next big
March 2, 2015 by Chain Drug Review and Chain Drug Review
50 Most Powerful Women in Corporate America, Black Enterprise, Claire Babineaux-Fontenot, Dedra Castle, Kathleen Wilson-Thompson, Rite Aid, Rosalind Brewer, Sam's Club, Walgreens Boots Alliance, Walmart
Business, Retail News
NEW YORK — Executives from Walmart, Sam’s Club, Rite Aid, Walgreens and Family Dollar Stores made Black Enterprise magazine’s “50 Most Powerful Women in Corporate America” list. Featured on the publication’s February 2015 cover, the list was culled from thousands of candidates across industries — including the finance, pharmaceutical and retail sectors — and the
February 16, 2015 by Mark Baumgartner and Chain Drug Review
Alliance Boots, George Fairweather, Marco Pagni, Stefano Pessina, Tim McLevish, Wade Miquelon, Walgreens, Walgreens Boots Alliance
Issue 02-16-2015, News
DEERFIELD, Ill. — Two Alliance Boots executives were promoted in recent weeks to new positions with Walgreens Boots Alliance Inc. (WBA). George Fairweather, formerly group finance director at Alliance Boots, was named WBA executive vice president and global chief financial officer. And Marco Pagni, who was Alliance Boots’ group legal counsel and chief administrative officer,
February 2, 2015 by Geoff Walden and Chain Drug Review
2014 Biennial Health Insurance Survey, Affordable Care Act, Commonwealth Fund, CVS Health, CVS/pharmacy, Health and Human Services Secretary, health care, health insurance, HHS, Mary Langowski, Ohio, Rite Aid, Sara Collins, Sylvia Burwell, Walgreens Boots Alliance
2015, Issue 02-02-2015, News
LAKEWOOD, Ohio — Highlighting the Obama administration’s partnerships with drug chains to boost health plan enrollment, Health and Human Services (HHS) Secretary Sylvia Burwell last month toured a CVS/pharmacy store here. Burwell’s visit also was intended to urge people to sign up for health insurance by the February 15 deadline in the current open enrollment period
February 2, 2015 by John Schultz and Chain Drug Review
AmerisourceBergen, board of directors, Greg Wasson, Ornella Barra, Richard Gozon, Steven Collis, Walgreens, Walgreens Boots Alliance
2015, Issue 02-02-2015, News
VALLEY FORGE, Pa. — Ornella Barra, executive vice president of Walgreens Boots Alliance Inc. (WBA), has been elected to the board of directors at AmerisourceBergen Corp. Barra, who also serves as president and chief executive officer of global wholesale and international retail, fills the vacancy created by Greg Wasson’s resignation from the board on January 9.
February 2, 2015 by Jeffrey Woldt and Chain Drug Review
Bartell Drugs, Bartell family, Canadian operations, chain drug industry, CVS Health, Dollar Tree, Family Dollar, Fred's, Jeffrey Woldt, Mike Bloom, NACDS, National Association of Chain Drug Stores, RediClinic, retail pharmacy, Rite Aid, RxImpact Day, Target, Walgreens Boots Alliance, Walmart
2015, Issue 02-02-2015, Opinion
The new year is just over a month old and already the chain drug industry has seen its fair share of noteworthy events. Walgreens Boots Alliance had a coming out party, opening trading at NASDAQ and unveiling its new corporate logo; Brian Unmacht became the first person outside the Bartell family to serve as president
January 19, 2015 by Mark Tosh and Chain Drug Review
Alliance Boots, CEO search, Greg Wasson, Jim Skinner, Nasdaq, Nasdaq MarketSite, Stefano Pessina, Walgreen Co., Walgreens Boots Alliance, WBA
2015, Issue 01-19-2015, News
NEW YORK — Walgreens Boots Alliance Inc.’s (WBA’s) top executives marked the close of a busy first week as a new company by ringing the opening bell January 9 at the Nasdaq Stock Market, where the company now trades under the “WBA” ticker symbol. Moments later, in an interview with financial network CNBC, executive vice chairman
January 19, 2015 by Geoff Walden and Chain Drug Review
ACA, Affordable Care Act, Department of Health and Human Services, health coverage, health insurance plan, HealthCare.gov, open enrollment, plan identification number, Richard Ashworth, Sylvia Burwell, Walgreens Boots Alliance, Walgreens pharmacy
2015, Issue 01-19-2015, News
WASHINGTON — Nearly 6.5 million consumers selected a health insurance plan or were automatically reenrolled under the Affordable Care Act in November and December. And 87% of people who selected 2015 plans through HealthCare.gov in the first month of open enrollment are getting subsidies to lower premiums, the government reported. “We’re pleased that nationwide, millions of
January 19, 2015 by Jeffrey Woldt and Chain Drug Review
Affordable Care Act, biotechnology, community pharmacy, CVS Health, health care system, Jeffrey Woldt, Kroger, National Association of Chain Drug Stores, pharmaceuticals, pharmacists, pharmacy operators, pharmacy practice, Rite Aid, Walgreen, Walgreens Boots Alliance, Walmart
2015, Issue 01-19-2015, Opinion
In the not-too-distant past community pharmacy was correctly perceived as a conservative business whose members were intent on operating within a well-defined set of parameters and not rocking the boat. A generation ago it wasn’t uncommon to hear members of the profession joke about what they did as “lick, stick and pour.” The industry as
January 9, 2015 by Chain Drug Review and Chain Drug Review
Greg Wasson, Jim Skinner, Nasdaq, Stefano Pessina, Walgreens, Walgreens Boots Alliance, WBA
Business, CDR Blog
Possibly lost in the fanfare surrounding the formal debut of Walgreens Boots Alliance, and its new home on the Nasdaq stock exchange, is the company’s new logo. Jim Skinner, executive chairman of WBA (the new stock symbol, by the way), told CNBC in the wake of the Nasdaq launch event in Manhattan that the company’s globe-shape logo
January 5, 2015 by Chain Drug Review
Alliance Boots, Dominic Murphy, Greg Wasson, Jim Skinner, KKR, merger, Stefano Pessina, Walgreens, Walgreens Boots Alliance, Walgreens shareholders, WBA
Business, Featured Articles, Retail News
DEERFIELD, Ill. – As expected, Walgreen Co. and Alliance Boots GmbH have finalized the second step of their two-part merger agreement following Walgreens shareholders’ approval earlier this week. Coming just before the new year, the completion of the deal announced in 2012 reorganizes Walgreens into a subsidiary of a new holding company, Walgreens Boots Alliance
January 5, 2015 by Mark Tosh and Chain Drug Review
Alliance Boots, Greg Wasson, James Skinner, Stefano Pessina, Walgreens, Walgreens Boots Alliance, William Foote
2015, Business, Issue 01-05-2015, News
DEERFIELD, Ill. — The New Year ushered in the beginning of a new era at Walgreen Co., which is scheduled to complete the second and final step of its merger with Alliance Boots GmbH in the first quarter. And this new era for Walgreens Boots Alliance will get under way without the presence of longtime
January 5, 2015 by David Pinto and Chain Drug Review
Alliance Boots, AmerisourceBergen, Bartell Drugs, Cardinal Health, chain drug industry, chain drug retailing, CVS Health, David Pinto, Greg Wasson, Kerr Drug, National Association of Chain Drug Stores, Rite Aid, Tony Civello, Walgreens, Walgreens Boots Alliance
2015, Issue 01-05-2015, Opinion
Which events were most significant for chain drug retailing in 2014? As usual, that is not an easy question to answer. In many ways, 2014 was a remarkable year for the chain drug industry, one in which the character of the business was changed, probably irrevocably. The industry assumed a global character for perhaps the